---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-017765"
form_type: "8-K"
ticker: "CNTA"
cik: "0001847903"
company_name: "Centessa Pharmaceuticals plc"
filed_at: "2023-01-27T23:59:59+00:00"
generated_at: "2026-06-20T07:23:32.233657+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Centessa enters ATM equity offering facility for up to $125M

## Summary
- Entered Sales Agreement with SVB Securities for at-the-market offering of ADS representing ordinary shares.
- Company may sell up to $125M of ADS at its discretion; no minimum offering amount required.
- SVB Securities to receive 3% commission on gross proceeds; company reimburses legal fees up to $150k.
- Net proceeds expected for working capital, capex, and general corporate purposes.
- No assurance of any sales; offering terminates upon full sale or agreement termination.

## SEC filing metadata
- accession: 0001193125-23-017765
- form_type: 8-K
- ticker: CNTA
- cik: 0001847903
- company_name: Centessa Pharmaceuticals plc
- filed_at: 2023-01-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/0001193125-23-017765-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/d418242d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-017765
- JSON: https://secwatch.observer/filing/0001193125-23-017765.json
- Plain text: https://secwatch.observer/filing/0001193125-23-017765.txt

## Key facts
- Material Agreements
  Centessa Pharmaceuticals plc entered into Sales Agreement with SVB Securities LLC valued at up to $125 million (effective 2023-01-27).
  - Action: entry
  - Agreement: atm program
  - Counterparty: SVB Securities LLC
  - Value: up to $125 million
  - Effective: 2023-01-27
  source text: On January 27, 2023, Centessa Pharmaceuticals plc (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with SVB Securities LLC (“SVB Securities”) with respect to an at-the-market offering program, under which the Company may, from time to time in its sole discretion, issue and sell through SVB Securities, acting as the Company’s sales agent, up to $125 million of the Company’s American Depositary Shares
  evidence_url: https://www.sec.gov/Archives/edgar/data/1847903/000119312523017765/0001193125-23-017765-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.